Redeye negatively views Surgical Science’s profit warning for Q2 2025.
SRV's net sales in Q2 amounted to EUR 168.7m, slightly below our estimate of EUR 174.
Redeye comments on Annexin Pharmaceuticals’ approval to start the phase IIa study in diabetic retino...
Redeye updates on G5 after weaker-than-expected Q2-results which have resulted in lowered estimates.
Redeye provides an update following Optomed’s Q2 2025 report.
CapMan's Q2 2025 results were largely in line with our expectations, with fee income declining sligh...
Rottneros reports SEK 140m impairment ahead of Q2 Challenging markets for Rottneros and Arctic Paper...
Adj. EBIT -29% vs FactSet consensus; FX adj sales -11% y-o-y Estimates to come down 8-10% on slower ...
Redeye provides an initial take following the release of Optomed’s Q2 2025 report.
DT’s Q2 revenue was slightly higher than expected, however the EUR 1.
Etteplan’s H1 was disappointing, with the escalation of the trade war causing demand to weaken furth...
Redeye comments on G5’s Q2-results where results were weaker than expected, partly driven by USD/SEK...
Redeye updates on Embracer ahead of Q1-results (due 14 August) where we forecast a slow start to 202...
New full year guidance for adjusted EBITDA in core businesses’ is EUR 16–20m in 2025 (previously EUR...
There were no surprises in Etteplan’s Q2 figures, since the company earlier issued a profit warning ...
